(RTTNews) – Shares of Tonix Pharmaceuticals Holding Corp. (TNXP), a New York-based biopharmaceutical company, are surging more than 38 percent or $0.59 in Tuesday’s morning trade at $2.14 despite no company-specific news influencing the stock.
U.S. stocks are rising on Tuesday in reaction to news that European Union leaders agreed to a 750 billion euro stimulus package to tackle the exceptional nature of the economic and social situation posed by the coronavirus pandemic. Upbeat earnings results from IBM Corp. and Coca-Cola also boosted sentiment.
Last Thursday, Tonix Pharmaceuticals said it entered into a research collaboration and option agreement with Columbia University to develop precision medicine techniques for COVID-19 vaccines and therapeutics.
The research collaboration will focus on T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19 at the cellular level, including human monoclonal antibodies and anti-idiotypes.
Tonix Pharmaceuticals has traded in a range of $0.39 to $5.90 in the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.